Seegene Inc
Seegene Inc maintains a strong liquidity position, with a current ratio of 4.68 and cash and equivalents amounting to KRW 225.57 billion, which is well above the industry median. The company's debt-to-equity ratio is 0.13, indicating a conservative capital structure with limited leverage. Profitability metrics show a return on equity (ROE) of 4.75% and a return on assets (ROA) of 3.91%, which are in line with the industry's preferred metrics. The company's operating income of KRW 26.15 billion and net income of KRW 48.27 billion reflect a healthy margin profile, although the gross profit margin of 64.1% suggests room for improvement in cost management. Geographically, Seegene's revenue is concentrated in South Korea, with a significant portion of its sales derived from domestic operations. The company has a limited presence in international markets, which may expose it to regional economic fluctuations and regulatory changes. The company's growth trajectory is positive, with a revenue of KRW 474.23 billion in the latest reporting period. While no specific growth rate is provided, the operating cash flow of KRW 149.33 billion and free cash flow of KRW 40.93 billion indicate strong cash generation capabilities. The capital expenditure of KRW -40.47 billion suggests a reduction in investment, which may signal a shift in strategic focus. Risk factors for Seegene include the potential for dilution, although the risk is currently assessed as low. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is minimal based on the current share structure. The risk assessment also indicates a low liquidity risk, supported by the company's strong cash reserves and low debt levels. Recent events, including analyst estimates and recommendations, suggest a generally positive outlook for Seegene. The mean price target of KRW 39,500 and the median price target of KRW 39,500 reflect a consensus among analysts. The mean recommendation of 1.50, with one strong-buy and one buy rating, indicates a favorable sentiment towards the stock.
Business. Seegene Inc is a South Korean biotechnology company that develops and commercializes molecular diagnostic solutions, primarily for infectious diseases and cancer, generating revenue through the sale of diagnostic kits and related services.
Classification. Seegene is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.
- Seegene Inc has a strong liquidity position with a current ratio of 4.68 and significant cash reserves.
- The company's profitability metrics, including ROE of 4.75% and ROA of 3.91%, are in line with industry standards.
- Revenue is heavily concentrated in South Korea, which may increase exposure to regional economic and regulatory risks.
- Analysts have a generally positive outlook, with a mean price target of KRW 39,500 and a mean recommendation of 1.50.
- The company's capital structure is conservative, with a low debt-to-equity ratio of 0.13 and minimal dilution risk.
- --
- ## RATIONALES
- ```json
- No immediate filing-based liquidity or dilution flags were detected.